Literature DB >> 1688102

Propranolol and thyroid hormone metabolism.

W M Wiersinga1.   

Abstract

Propranolol decreases plasma T3 and increases plasma rT3 in a dose-dependent manner due to a decreased production rate of T3 and a decreased metabolic clearance rate of rT3, respectively, caused by inhibition of the conversion of T4 into T3 and of rT3 into 3,3'-T2. This inhibition of 5'-deiodination is not secondary to inhibition of thyroid hormone transport across the plasma membrane. Propranolol and its major metabolite, 4-hydroxypropranolol, are not directly responsible for these effects, but an unidentified metabolite of propranolol might be involved. beta-blockers ameliorate clinical symptoms and signs of thyrotoxicosis independent of the decrease of plasma 13, that is confined to beta-blockers with membrane-stabilizing activity, such as propranolol and alprenolol. The decrease of plasma T3, however, appears responsible for some of the metabolic responses to beta-blockers.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1688102     DOI: 10.1089/thy.1991.1.273

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  12 in total

Review 1.  Thyroid emergencies.

Authors:  Joanna Klubo-Gwiezdzinska; Leonard Wartofsky
Journal:  Med Clin North Am       Date:  2012-02-17       Impact factor: 5.456

2.  Endocrine disruption as an adverse effect of non-endocrine targeting pharmaceuticals.

Authors:  Shakila Sabir; Muhammad Furqan Akhtar; Ammara Saleem
Journal:  Environ Sci Pollut Res Int       Date:  2018-11-22       Impact factor: 4.223

3.  Relationship between metabolic syndrome and multinodular non-toxic goiter in an inpatient population from a geographic area with moderate iodine deficiency.

Authors:  D Rendina; G De Filippo; G Mossetti; G Zampa; R Muscariello; G Benvenuto; C L Vivona; S Ippolito; F Galante; G Lombardi; B Biondi; P Strazzullo
Journal:  J Endocrinol Invest       Date:  2011-07-05       Impact factor: 4.256

4.  Depression and thyroid axis function in coronary artery disease: impact of cardiac impairment and gender.

Authors:  Robertas Bunevicius; Giedrius Varoneckas; Arthur J Prange; Alan L Hinderliter; Vilte Gintauskiene; Susan S Girdler
Journal:  Clin Cardiol       Date:  2006-04       Impact factor: 2.882

Review 5.  An update on the medical treatment of Graves' hyperthyroidism.

Authors:  Michele Marinò; Francesco Latrofa; Francesca Menconi; Luca Chiovato; Paolo Vitti
Journal:  J Endocrinol Invest       Date:  2014-09-04       Impact factor: 4.256

6.  Thyroid hormone modulates glucose production via a sympathetic pathway from the hypothalamic paraventricular nucleus to the liver.

Authors:  Lars P Klieverik; Sarah F Janssen; Annelieke van Riel; Ewout Foppen; Peter H Bisschop; Mireille J Serlie; Anita Boelen; Mariëtte T Ackermans; Hans P Sauerwein; Eric Fliers; Andries Kalsbeek
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-24       Impact factor: 11.205

Review 7.  A Review of the Pharmacokinetics of Levothyroxine for the Treatment of Hypothyroidism.

Authors:  Philippe Colucci; Corinne Seng Yue; Murray Ducharme; Salvatore Benvenga
Journal:  Eur Endocrinol       Date:  2013-03-15

8.  Prediction of infarct severity from triiodothyronine levels in patients with ST-elevation myocardial infarction.

Authors:  Dong Hun Kim; Dong-Hyun Choi; Hyun-Wook Kim; Seo-Won Choi; Bo-Bae Kim; Joong-Wha Chung; Young-Youp Koh; Kyong-Sig Chang; Soon-Pyo Hong
Journal:  Korean J Intern Med       Date:  2014-06-27       Impact factor: 2.884

Review 9.  Abnormalities of Thyroid Hormone Metabolism during Systemic Illness: The Low T3 Syndrome in Different Clinical Settings.

Authors:  Arnaldo Moura Neto; Denise Engelbrecht Zantut-Wittmann
Journal:  Int J Endocrinol       Date:  2016-10-10       Impact factor: 3.257

Review 10.  Perioperative Management of Thyroid Dysfunction.

Authors:  Marcia Rashelle Palace
Journal:  Health Serv Insights       Date:  2017-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.